|
Exchange: |
|
Security
Type: |
|
Shares
Out: |
29,810,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
|
Level
II Sector: |
|
Level
III Sector: |
|
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Silence Therapeutics and its subsidiaries are involved in the discovery, delivery and development of short interfering ribonucleic acid to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with unmet medical need. Co.'s mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of medicines designed to target and silence specific disease-associated genes in the liver. Co.'s wholly owned clinical development programs include SLN360 for the unmet need in reducing cardiovascular risk in people born with high Lipoprotein(a) levels and SLN124 for rare iron loading anemia conditions, including thalassemia and myelodysplastic syndrome.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|